FDA Brief

Warning letters Food

FDA warning letter to

Anna Health, LLC

High riskIssued Mar 16, 2021Posted Mar 30, 2021Division of Human and Animal Food Operations East IV

FDA warned Anna Health that website claims made its supplements unapproved drugs, including Immune Health for COVID-19.

What happened

From October 2020 to March 2021, FDA reviewed www.annahealth.com and found it took orders for Fucoidan, Prostate Health, Children Liquid Vitamins, and Immune Health. The site claimed these products treated cancer, enlarged prostate, anemia, anxiety, and COVID-19, among other conditions. FDA said the claims make the products unapproved new drugs and misbranded because their directions are not adequate for safe lay use.

What FDA found

  1. Website claims show Fucoidan, Prostate Health, Children Liquid Vitamins, and Immune Health are intended to treat disease.

    section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 321(g)(1)(B)]
  2. The products are unapproved new drugs, meaning products that need FDA approval before sale, because FDA has not found them safe and effective for those uses.

    sections 301(d) and 505(a) [21 U.S.C. 331(d), 355(a)]
  3. The products are misbranded because they lack adequate directions for safe use by a layperson for diseases that need a licensed practitioner.

    section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. The misbranded products were introduced or delivered for introduction into interstate commerce.

    section 301(a) [21 U.S.C. 331(a)]

What FDA wants

FDA asks Anna Health to take immediate action to stop selling any unapproved or unauthorized products claimed for COVID-19. It also asks the company to notify FDA in writing within 15 working days of steps taken to fix violations, or explain any delay and set a completion time.

Who should pay attention

  • online sellers of dietary supplements
  • retailers and brands selling immune or prostate products
  • companies making disease-treatment claims on product websites

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk